| Species |
Mouse |
| Protein Construction |
ADAM8 (Pro17-Ser658)_x000D_
Accession # Q05910 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave a fluorogenic peptide substrate McaPLAQAVDpaRSSSRNH2. The specific activity is > 0.4 pmol/min/µg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
71.7 kDa |
| Apparent Molecular Weight |
The protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
A Disintegrin And Metalloproteinase (ADAM) proteases constitute a family of multifunctional, membrane-bound proteins with traditional sheddase functions. Their protumorigenic potential has been attributed to both, essential (ADAM10 and ADAM17) and 'dispensable' ADAM proteases (ADAM8, 9, 12, 15, and 19). Of specific interest in this review is the ADAM proteinase ADAM8 that has been identified as a significant player in aggressive malignancies including breast, pancreatic, and brain cancer. |
| Synonyms |
ADAM 8; Ms2; Adam8; CD156a; MGC134985 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
